Filing Analysis
Dogwood Therapeutics held its annual meeting of stockholders on June 16, 2026, where shareholders approved an amendment to the Certificate of Incorporation to increase the number of authorized common and preferred shares. The company also ratified its auditor and elected its board of directors.
🚩 Red Flags
- Increase in authorized shares often precedes dilutive equity offerings, which is a common risk for micro-cap companies.
📋 Key Facts
- Stockholders approved an amendment to the Certificate of Incorporation to increase authorized shares of common and preferred stock (Proposal 3).
- The amendment was filed with the Secretary of State of Delaware on June 17, 2026.
- Forvis Mazars, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Seven directors were elected to the board.
- Stockholders approved 'Say-on-Pay' and voted for an annual frequency for future executive compensation votes.
Dogwood Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing was made on May 14, 2026, to report results for the quarter ended March 31, 2026.
- The disclosure was made under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the operations was included as Exhibit 99.1.
- The information in the report is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Dogwood Therapeutics, Inc. released a shareholder letter on March 26, 2026, providing a corporate update to investors. The information was furnished as a Regulation FD disclosure and is not deemed 'filed' for legal liability purposes.
📋 Key Facts
- Shareholder letter dated March 26, 2026, was posted to the company website.
- The filing includes a corporate update intended for shareholders.
- Information is furnished under Item 7.01 and is not incorporated by reference into Securities Act filings.
Dogwood Therapeutics, Inc. (DWTX) announced its financial results for the fourth quarter and full year ended December 31, 2025. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing was made on March 18, 2026, to report results for the period ended December 31, 2025.
- The company furnished the information under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial performance was included as Exhibit 99.1.
- The company is a Delaware corporation trading on the Nasdaq Capital Market.
Dogwood Therapeutics held a Special Meeting on March 11, 2026, where shareholders approved the potential exercise of unregistered common stock warrants for up to 4,386,037 shares. This approval was required to comply with Nasdaq Listing Rule 5635(d) following a Securities Purchase Agreement with a single institutional investor dated January 11, 2026.
📋 Key Facts
- Special Meeting held on March 11, 2026, with 88.03% of voting power represented.
- Shareholders approved the issuance of up to 4,386,037 shares of common stock upon the exercise of warrants.
- The warrants were issued pursuant to a Securities Purchase Agreement dated January 11, 2026, with a single institutional investor.
- Approval satisfies Nasdaq Listing Rule 5635(d) regarding the issuance of 20% or more of the company's outstanding common stock.
- Proposal 1 received 29,286,786 'For' votes versus 19,057 'Against' votes.